posted on 2020-09-24, 16:36authored bySrijit Mukherjee, Sheng-Ting Hung, Nancy Douglas, Premashis Manna, Connor Thomas, Annika Ekrem, Amy E. Palmer, Ralph Jimenez
The
development of fluorescent proteins (FPs) has revolutionized
biological imaging. FusionRed, a monomeric red FP (RFP), is known
for its low cytotoxicity and correct localization of target fusion
proteins in mammalian cells but is limited in application by low fluorescence
brightness. We report a brighter variant of FusionRed, “FR-MQV,”
which exhibits an extended fluorescence lifetime (2.8 ns), enhanced
quantum yield (0.53), higher extinction coefficient (∼140 000
M–1 cm–1), increased radiative
rate constant, and reduced nonradiative rate constant with respect
to its precursor. The properties of FR-MQV derive from three mutationsM42Q,
C159V, and the previously identified L175M. A structure-guided approach
was used to identify and mutate candidate residues around the para-hydroxyphenyl
and the acylimine sites of the chromophore. The C159V mutation was
identified via lifetime-based flow cytometry screening of a library
in which multiple residues adjacent to the para-hydroxyphenyl site
of the chromophore were mutated. The M42Q mutation is located near
the acylimine moiety of the chromophore and was discovered using site-directed
mutagenesis guided by X-ray crystal structures. FR-MQV exhibits a
3.4-fold higher molecular brightness and a 5-fold increase in the
cellular brightness in HeLa cells [based on fluorescence-activated
cell sorting (FACS)] compared to FusionRed. It also retains the low
cytotoxicity and high-fidelity localization of FusionRed, as demonstrated
through assays in mammalian cells. These properties make FR-MQV a
promising template for further engineering into a new family of RFPs.